• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


Prices delayed by at least 15 minutes | Print

EVOTEC SE INH O.N. (EVT)

Inhaber-Aktien o.N.
Sell: €9.76|Buy: €9.76|Change: 0.14 (-1.36%)

This share can be held in a Dealing accountISALifetime ISAJISASIPP

Company profile

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The EVT Execute segment, about 65% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment, about 35% of sales, develops proprietary drug discovery programs and assets, which can lead to partnerships with clients. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Address

Manfred Eigen Campus
Essener Bogen 7
Hamburg
DEU
22419

Telephone

+49 040 56081286

Website

https://www.evotec.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Evotec SE Fourth Quarter Earnings Conference Call for 20242025-04-24T09:00:00
Evotec SE Fourth Quarter Earnings Results for 20242025-04-24T00:00:00
Evotec SE Annual Report for 20242025-04-24T00:00:00
Evotec SE Third Quarter Earnings Results for 20242024-11-08T00:00:00
Evotec SE Third Quarter Earnings Conference Call for 20242024-11-08T00:00:00
Evotec SE Second Quarter Earnings Results for 20242024-08-29T00:00:00
Evotec SE Second Quarter Earnings Conference Call for 20242024-08-29T00:00:00
Evotec SE Annual General Meeting for 20242024-06-20T10:00:00
Evotec SE First Quarter Earnings Result for 20242024-05-30T00:00:00
Evotec SE First Quarter Earnings Conference Call for 20242024-05-30T00:00:00

Previous key dates

NameKey Date
Evotec SE First Quarter Earnings Result for 20242024-05-30T00:00:00
Evotec SE First Quarter Earnings Conference Call for 20242024-05-30T00:00:00
Evotec SE Fourth Quarter Earnings Conference Call for 20232024-04-24T09:00:00
Evotec SE Fourth Quarter Earnings Result for 20232024-04-24T00:00:00
Evotec SE Annual Report for 20232024-04-24T00:00:00
Evotec SE: Invitation to Conference Call2024-01-22T09:00:00
Evotec SE Third Quarter Earnings Result for 20232023-11-08T00:00:00
Evotec SE Third Quarter Earnings Conference Call for 20232023-11-08T00:00:00
Evotec SE Second Quarter Earnings Result for 20232023-08-29T00:00:00
Evotec SE Second Quarter Earnings Conference Call for 20232023-08-29T00:00:00
Evotec SE Annual General Meeting for 20232023-06-20T10:00:00
Evotec SE First Quarter Earnings Results for 20232023-05-12T00:00:00
Evotec SE Annual Report for 20222023-05-12T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.